IMIPRAMINE PAMOATE

Post-LOE

imipramine pamoate

Hikma

ANDAORALCAPSULE

Approved

Jun 2013

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

IMIPRAMINE PAMOATE (imipramine pamoate) by Hikma is clinical pharmacology the mechanism of action of imipramine is not definitely known. Approved for depression. First approved in 2013.

Drug data last refreshed 22h ago

Mechanism of Action

CLINICAL PHARMACOLOGY The mechanism of action of imipramine is not definitely known. However, it does not act primarily by stimulation of the central nervous system. The clinical effect is hypothesized as being due to potentiation of adrenergic synapses by blocking uptake of norepinephrine at nerve…

Indications (1)

depression

Company

Worked on IMIPRAMINE PAMOATE at Hikma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.